Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABX464-101

44 evidence topics · 12 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Allocation“Randomized”
Interventional model“Parallel Assignment”
Interventional model description“Double-blind, placebo-controlled, randomized study”
Masking description“Double-Blind Treatment”
Primary purpose“Treatment”
Phase“Phase 2”
Enrollment (actual)“32”
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the posted results
AnalysisABX464Placebo
Baseline and safety analysis“23”“9”
Efficacy outcomes (total Mayo score, partial Mayo score, fecal calprotectin)“20”“9”
Description of analysis sets
Statistical tests in the posted results
OutcomeMethod
Treatment-emergent adverse events“Chi-squared”
Clinical remission“Chi-squared”
Fecal calprotectin“ANCOVA”
Total Mayo score“ANCOVA”
Partial Mayo score“ANCOVA”
Results
Participant disposition
Participant flow in the posted results
MilestoneABX464Placebo
Started“23”“9”
Completed“21”“9”
Not completed“2”“0”
Reason not completed: adverse event“1”“0”
Reason not completed: withdrawal by subject“1”“0”
Baseline characteristics
Age, sex, and race in the posted results
CharacteristicABX464 (N=23)Placebo (N=9)Total (N=32)
Age between 18 and 65 years“19”“9”“28”
Age 65 years or older“4”“0”“4”
Female“11”“1”“12”
Male“12”“8”“20”
White“23”“9”“32”
Baseline disease activity, disease duration, and prior advanced therapy

No evidence found.

Efficacy results
Clinical remission at week 8 in the posted results, with arm titles as the record lists them
FieldFirst arm listedSecond arm listed
Arm/group title“ABX464 Matching Placebo Treatment Arm”“ABX464 Treatment Arm”
Overall number of participants analyzed“20”“9”
Participants in clinical remission“7”“1”
Mayo score change and fecal calprotectin at week 8 in the posted results
OutcomeABX464 (n=20)Placebo (n=9)
Change from baseline in total Mayo score, mean (SD)“-4.6(2.8)”“-2.1(2.5)”
Change from baseline in partial Mayo score, mean (SD)“-3.9(2.2)”“-1.8(2.0)”
Participants with fecal calprotectin above 50 µg/g“15”“8”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Participants with treatment-emergent adverse events (primary outcome)
MeasureABX464Placebo
Overall number of participants analyzed“23”“9”
Participants with treatment-emergent adverse events“18”“5”
Time frame“Week 8”“Week 8”
Deaths, serious adverse events, and other adverse events in the posted results
Measure, affected / at risk (%)ABX464Placebo
All-cause mortality“0/23 (0.00%)”“0/9 (0.00%)”
Serious adverse events, total“0/23 (0.00%)”“1/9 (11.11%)”
Nephrolithiasis left side (serious)“0/23 (0.00%)”“1/9 (11.11%)”
Other (not including serious) adverse events, total“18/23 (78.26%)”“5/9 (55.56%)”
Other adverse events in at least two participants of either group
Study limitations
Summary

ABX464-101 was a randomized, double-blind, placebo-controlled phase 2a study in which 32 participants with moderately to severely active ulcerative colitis were randomized 2:1 to obefazimod 50 mg (23 participants) or placebo (9 participants) once daily for 8 weeks, at sites in six European countries. The registered primary endpoint was the number of participants with treatment-emergent adverse events; clinical remission by the total Mayo score at week 8 was registered as an outcome described as the “primary efficacy endpoint”. Efficacy was analyzed in participants without major protocol deviations who completed day 56 (20 receiving obefazimod and 9 receiving placebo), and the sponsor reported that 29 of the 32 participants “completed the study per protocol”. The planned sample size, stated in the ABX464-102 protocol, was a maximum of 30 participants, and no power calculation was located. Clinical remission at week 8 was reported as 35.0% with obefazimod and 11.1% with placebo, a difference the sponsor reported as not significant. The posted record lists the arm titles of the clinical remission outcome in the reverse order of the other outcomes, so its arm labels do not match its participant counts. The posted results analyze the change in partial and total Mayo scores by ANCOVA, whereas a 2019 press release reports p=0.029 for both, naming a likelihood ratio chi-square test for the partial Mayo score, and the 2018 topline release reports p<0.03 for the total Mayo score. Placebo clinical response is given as 33.0% in the ABX464-102 protocol and 33.3% in a 2021 press release. The sponsor describes the study drug as a tablet, and the posted record as a capsule. All 32 participants were White. Baseline disease activity, disease duration, and prior advanced therapy exposure were not reported in the readable sources, because the protocol and statistical analysis plan posted on ClinicalTrials.gov are image-only scans. No health-related quality of life results were located.